Nuvalent, Inc.
neladalkib
ALK-positive NSCLC
Resolved
7days ago
Catalyst readout · ~ Jun 30, 2026 estimated
What's at stake
A key catalyst for neladalkib (ALK-positive NSCLC) is expected ~ Jun 30, 2026.
Primary source
· SEC 8-K
verified 15h ago
“NDA submission for neladalkib in TKI pre-treated advanced ALK-positive NSCLC population planned for the first half of 2026”